These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 18223031)

  • 1. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Zinman B; Lachin JM; Haffner SM; Herman WH; Holman RR; Kravitz BG; Yu D; Heise MA; Aftring RP; Viberti G;
    Diabetes Care; 2008 May; 31(5):845-51. PubMed ID: 18223031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rosiglitazone, metformin, and glyburide on bone biomarkers in patients with type 2 diabetes.
    Zinman B; Haffner SM; Herman WH; Holman RR; Lachin JM; Kravitz BG; Paul G; Jones NP; Aftring RP; Viberti G; Kahn SE;
    J Clin Endocrinol Metab; 2010 Jan; 95(1):134-42. PubMed ID: 19875477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones and fractures in men and women.
    Dormuth CR; Carney G; Carleton B; Bassett K; Wright JM
    Arch Intern Med; 2009 Aug; 169(15):1395-402. PubMed ID: 19667303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.
    Mancini T; Mazziotti G; Doga M; Carpinteri R; Simetovic N; Vescovi PP; Giustina A
    Bone; 2009 Oct; 45(4):784-8. PubMed ID: 19527806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary heart disease outcomes in patients receiving antidiabetic agents.
    McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
    Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distal upper and lower limb fractures associated with thiazolidinedione use.
    Jones SG; Momin SR; Good MW; Shea TK; Patric K
    Am J Manag Care; 2009 Aug; 15(8):491-6. PubMed ID: 19670952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
    Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
    J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 short-term, double-blind, randomized clinical studies with rosiglitazone.
    Cobitz A; Zambanini A; Sowell M; Heise M; Louridas B; McMorn S; Semigran M; Koch G
    Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):769-81. PubMed ID: 18613278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
    Feig DS; Briggs GG; Koren G
    Ann Pharmacother; 2007 Jul; 41(7):1174-80. PubMed ID: 17535842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer and bone fractures in observational follow-up of the RECORD study.
    Jones NP; Curtis PS; Home PD
    Acta Diabetol; 2015 Jun; 52(3):539-46. PubMed ID: 25524432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.
    Viberti G; Kahn SE; Greene DA; Herman WH; Zinman B; Holman RR; Haffner SM; Levy D; Lachin JM; Berry RA; Heise MA; Jones NP; Freed MI
    Diabetes Care; 2002 Oct; 25(10):1737-43. PubMed ID: 12351470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).
    Kahn SE; Haffner SM; Viberti G; Herman WH; Lachin JM; Kravitz BG; Yu D; Paul G; Holman RR; Zinman B;
    Diabetes Care; 2010 Jan; 33(1):177-83. PubMed ID: 19808911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone.
    Yener S; Comlekci A; Akinci B; Demir T; Yuksel F; Ozcan MA; Bayraktar F; Yesil S
    Med Princ Pract; 2009; 18(4):266-71. PubMed ID: 19494532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of long-term treatment with rosiglitazone on arterial elasticity and metabolic parameters in patients with Type 2 diabetes mellitus: a 2-year follow-up study.
    Shargorodsky M; Michaelova K; Boaz M; Gavish D; Zimlichman R
    Diabet Med; 2007 Nov; 24(11):1254-60. PubMed ID: 17725634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France.
    Vexiau P; Mavros P; Krishnarajah G; Lyu R; Yin D
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():16-24. PubMed ID: 18435670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.